Tolebrutinib is more effective in reducing the risk of disability progression in MS patients with paramagnetic rim lesions, ...

While Sanofi's list price of Aubagio is set at £13,529 ($22,100) per patient a year, NICE was able to recommend it for the NHS after Sanofi made the drug available at a discount under the patient ...

Morningstar brands and products Company Portfolio ...

However, two other trials in relapsing forms of MS – GEMINI 1 and 2 – were unable to show an improvement over Sanofi's older therapy Aubagio (teriflunomide). The company said at the time it ...

TG Therapeutic, Inc. stock soars on Briumvi success, strong Q4 results, and promising 2025 outlook. Click to discover the ...

The risk of disease activity in going to a less effective DMT was higher in younger adults and those having prior ...

In collaborative work, Trethera and the Peter Clark Lab at UCLA have shown that when autoreactive T and B cells divide, they activate the TRE-515 target dCK. In those abnormally activated cells, dCK ...